Veryan Presents Two-Year Results from Randomised Controlled Study of BioMimics 3D® Stent at New Cardiovascular Horizons Conference.

New Orleans, 30th May 2014 – Seroba Kernel investee company, Veryan, presented Full two-year data from the Mimics study at the 15th Annual New Cardiovascular Horizons (NCVH) Conference in New Orleans. The data confirmed that BioMimics 3D™ provides a significant improvement in long-term patency compared to a straight nitinol control stent in patients undergoing femoropopliteal artery intervention. BioMimics 3D, a nitinol stent with unique three-dimensional helical geometry, has been developed by Veryan, based on pioneering research by Prof Colin Caro at Imperial College London into the link between blood flow mechanics and vascular disease.

The Mimics study is a prospective, randomised, multicenter controlled trial conducted at eight German investigational centers and supported by an independent core lab. A total of 76 patients were enrolled and randomized 2:1 (50 BioMimics 3D v 26 Control) in patients undergoing femoropopliteal artery intervention. Mimics’ investigators compared the safety, efficacy and vascular hemodynamics of the BioMimics 3D stent to straight nitinol stents (24/26 control subjects were treated with C.R. Bard’s LifeStent).

The BioMimics 3D stent incorporates Veryan’s patented 3D helical technology, an advanced stent design that promotes natural swirling blood flow to elevate wall shear stress which has been shown to reduce neointimal hyperplasia and improve the biomechanical performance of the femoropopliteal artery during knee flexion, mitigating the risk of stent fracture and vessel kinking.

The full two-year data from Mimics were presented by Principal Investigator Professor Thomas Zeller, Universitäts-Herzzentrum, Freiburg-Bad Krozingen, Germany. There are two key findings; firstly, the Kaplan Meier (KM) survival analysis of freedom from loss of primary patency at two years was 72% for BioMimics 3D subjects vs. 55.0% for the control group: a significant difference (P=0.0497). Secondly, there was no increase in the clinically driven target lesion revascularisation (CDTLR) rate in the BioMimics arm between 12 and 24 months (9% at both time-points) compared to an increase of 16% (8% at 12 months and 24% at 24 months) in the control arm. The data indicate a correlation between primary patency and stent curvature. BioMimics 3D stented segments showed significantly greater curvature (P= 0.02) compared with the control, providing improved blood flow and elevated wall shear, which may explain the longer term patency protective effect seen with BioMimics 3D. No stent fractures were detected by the independent core lab.

“The final 24-month data for the BioMimics 3D stent confirm that the flow effects produced by its helical design are contributing to an improved outcome compared to that achieved with the straight control stents. The results of the Mimics study show a significantly greater freedom from loss of primary patency with BioMimics in the 24-month Kaplan Meier survival analysis”, commented Professor Zeller. “Importantly, there was no change in the rate of clinically-driven target lesion revascularization in the 12 and 24 month follow-ups for BioMimics 3D and this longer-term benefit appears to correlate with a trend to lower peak systolic velocities. Overall, these data suggest that a biomimetic stent with 3D helical curvature may provide a new performance benchmark in femoropopliteal stenting”.

“We are very grateful to Professor Zeller and the Mimics Investigators for the support that has enabled Veryan to complete this benchmark evaluation of our biomimetic 3D helical stent technology. We believe this advanced stent design offers outstanding benefits in femoropopliteal use and has potential for innovation in many other areas of endovascular intervention. Presentation of the full two-year Mimics results represents a major step forward in this endeavour”, added Veryan Chief Executive Chas Taylor.

Veryan has received CE Mark approval for the BioMimics 3D stent and plans to commercialise the stent later this year.

Ends.
 

For further information, please contact:
Vicky La Touche-Price, Seroba Kernel Life Sciences: +353 1 6334028.

 

< back to home page